FGF23

Real-World Evidence Confirms Burosumab Effectiveness Across All Ages in X-linked Hypophosphatemia

A 3-year prospective study demonstrates sustained biochemical and clinical improvements with burosumab in XLH patients across pediatric and adult age groups, including those typically excluded from clinical trials.